Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXHealthcare · Biotechnology
-6.17%$9.13
AH$8.98-1.65%vs close
Mkt Cap$604.16M
Float43.17M
O/S66.17M
Vol
$ Vol
RVOL
Inst Own-
SI23.9%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$137.95M
Total Assets$430.99M
Free Cash Flow-$107.11M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$1.71M
Total Equity$401.45M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in BCAX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$430.99M
Liabilities$29.54M
Accounts Receivable$0
Accounts Payable$7.79M
Inventory$0
PP&E (Net)$2.03M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - |
| Research and Development | $125.1M | $63.62M | $30.62M | $31.31M |
| Selling, General, and Administrative | $30.51M | $18.77M | $9.27M | $6.34M |
| Other | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $155.6M | $82.39M | $39.89M | $37.66M |
| Operating Income (EBIT) | -$155.6M | -$82.39M | -$39.89M | -$37.66M |
| Operating Margin | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $112K |
| Interest Income | $17.87M | $14.58M | $1.31M | $4K |
| Other Income (Expense) | $17.87M | $14.58M | -$12.09M | -$188K |
| Income Before Tax (EBT) | -$137.73M | -$67.81M | -$51.98M | -$37.84M |
| Income Tax Expense | $217K | $187K | $5K | $1K |
| Net Income | -$137.95M | -$68M | -$51.98M | -$37.84M |
| Net Income Margin | - | - | - | - |
| Supplementary Data | ||||
| EPS | -2.52 | -1.25 | -1.00 | -0.73 |
| Diluted EPS | -2.52 | -1.25 | -1.00 | -0.73 |
| Weighted Average OS | 54.68M | 54.42M | 51.76M | 51.76M |
| EBITDA | -$137.63M | -$67.75M | -$51.96M | -$37.72M |
| EBITDA Margin | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $96.69M | $489.71M | $230.44M | $4.16M |
| Short-Term Investments | $318.12M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $414.8M | $489.71M | $230.44M | $4.16M |
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Current Assets | $7.25M | $12.82M | $100K | $68K |
| Total Current Assets | $422.05M | $502.53M | $231.07M | $4.98M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $2.03M | $845K | $815K | $636K |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $59.2M | $0 | $0 |
| Other Long-Term Assets | $6.91M | $6.62M | $2.09M | $1.08M |
| Total Long-Term Assets | $8.94M | $66.66M | $2.91M | $1.72M |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $430.99M | $569.2M | $233.98M | $6.7M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $7.79M | $4.51M | $3.19M | $5.14M |
| Short-Term Debt | $0 | $607K | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $5.04M | $9.79M | $1.74M | $17.58M |
| Total Current Liabilities | $28.95M | $17.99M | $15.09M | $23.9M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $59.2M | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $17K | $85K |
| Total Long-Term Liabilities | $593K | $59.33M | $389K | $85K |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $29.54M | $77.32M | $15.47M | $23.98M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $0 | $367.28M | $81.53M |
| Common Stock | $7K | $7K | $2K | $2K |
| Retained Earnings | -$358.97M | -$221.02M | -$153.02M | -$101.04M |
| Comprehensive Income & Other | $243K | $0 | $0 | $0 |
| Other Stockholders' Equity | $760.41M | $712.88M | $371.53M | $83.76M |
| Total Equity | $401.45M | $491.88M | $218.51M | -$17.28M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $430.99M | $569.2M | $233.98M | $6.7M |
| Supplementary Data | ||||
| Total Debt | $1.71M | $738K | $657K | $0 |
| Net Debt | -$94.97M | -$488.97M | -$229.78M | -$4.16M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$137.95M | -$68M | -$51.98M | -$37.84M |
| Depreciation & Amortization | $105K | $56K | $19K | $10K |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $15.01M | $7.4M | $1.9M | $810K |
| Changes in Working Capital: | ||||
| Accounts Receivable | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $2.64M | $0 | $0 |
| Other Working Capital | $14.81M | -$16.77M | -$9.62M | $4.95M |
| Total Working Capital Change | $14.81M | -$14.13M | -$9.62M | $4.95M |
| Other Non-Cash Items | $1.2M | -$77K | $14.06M | $0 |
| Net Cash from Operating | -$106.83M | -$74.75M | -$45.63M | -$32.08M |
| Investing Activities | ||||
| Capital Expenditures | -$280K | -$71K | -$586K | -$192K |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$318.17M | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $62K | $0 | $0 |
| Net Cash from Investing | -$318.45M | -$9K | -$586K | -$192K |
| Financing Activities | ||||
| Debt Repaid | - | - | - | - |
| Common Stock Issuance | $32.26M | $332.43M | $0 | $160K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $1.6M | $149K | $0 |
| Net Cash from Financing | $32.26M | $334.03M | $272.5M | $31.7M |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$393.03M | $259.27M | $226.28M | -$573K |
| Supplementary Data | ||||
| Operating Cash Flow | -$106.83M | -$74.75M | -$45.63M | -$32.08M |
| Capital Expenditure | -$280K | -$71K | -$586K | -$192K |
| Free Cash Flow | -$107.11M | -$74.82M | -$46.21M | -$32.27M |
| Cash at Beginning | $489.71M | $230.44M | $4.16M | $4.73M |
| Cash at End | $96.69M | $489.71M | $230.44M | $4.16M |